Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Tmem16A Limited currently faces 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This active prosecution is located within 1 distinct art unit, indicating a specialized area of technical review. The portfolio's current activity involves 1 distinct examiner, which centralizes the communication and negotiation process for the applicant. This structure implies that the company's current patenting efforts are concentrated on a specific biological or pharmaceutical innovation.
O DELL, DAVID K serves as the busiest examiner, managing 1 pending office action. This individual handles the only pending action currently recorded for the company. Because the workload is limited to the single examiner and single art unit, the prosecution environment is highly focused, requiring the applicant to address the specific requirements of O DELL, DAVID K. This singular focus can simplify the prosecution strategy by removing the need to manage multiple examiner relationships.
The current volume of activity suggests a targeted approach to intellectual property development. With only the single art unit involved, the company can dedicate its resources to satisfying the specific technical and legal standards of the assigned examiner. This concentrated prosecution profile within the Biotechnology & Pharmaceuticals area allows for a clear and direct path toward resolving the outstanding office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| O DELL, DAVID K | 1 | 57.8% | +35.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18332551 | BENZIMIDAZOLE DERIVATIVES FOR TREATING RESPIRATORY DISEASE | O DELL, DAVID K | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18332551 | BENZIMIDAZOLE DERIVATIVES FOR TREATING RESPIRATORY DISEASE | O DELL, DAVID K | 1621 | DP | Final Rejection | — | Pending | Jun 09, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTmem16A Limited has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
David K O Dell has the most, with 1 of Tmem16A Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.